Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
47.32 USD | +2.25% | +0.98% | +33.00% |
Jun. 04 | Oppenheimer Raises Price Target on Crinetics Pharmaceuticals to $74 From $55, Maintains Outperform Rating | MT |
Jun. 03 | Transcript : Crinetics Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.00% | 3.65B | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- CRNX Stock
- News Crinetics Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing